Topics

Latest "IONTAS" News Stories

03:45 EST 27th February 2020 | BioPortfolio

Here are the most relevant search results for "IONTAS" found in our extensive news archives from over 250 global news sources.

More Information about IONTAS on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about IONTAS for you to read. Along with our medical data and news we also list IONTAS Clinical Trials, which are updated daily. BioPortfolio also has a large database of IONTAS Companies for you to search.

Showing "IONTAS" News Articles, all 13

Tuesday 24th December 2019

Adaptate and Iontas’ partner on antibody selection and optimization

Adaptate gains access to Iontasâ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.


Adaptate and Iontas partner on antibody selection and optimization

Adaptate gains access to Iontasâ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.

Monday 16th December 2019

Abzena Hosts Second Biopharmaceutical Discovery and Development Symposium in Cambridge, UK on 19th February 2020

Abzena, the global biologics target-to-GMP Partner Research Organisation today announces it is hosting the second Biopharmaceutical Discovery and Development Symposium at the Babraham Research Campus in Cambridge on 19th February 2020. The Symposium will highlight the latest technologies and advancements in the biopharmaceutical discovery and development field by Abzena and its partners, and ho...


Monday 9th December 2019

IONTAS antibody enters clinical trial for use in the treatment of B cell Acute Lymphoblastic Leukemia.

Cambridge, UK and Moscow, Russia, 09 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that International Biotechnology Center (IBC) Generium, a leading Russian biopharmaceutical company, focused on developing and commercialising pharmaceutical products for the treatment of orphan diseases and cancer, has received appr...

IONTAS Antibody Enters Clinical Trial for Use in the Treatment of B Cell Acute Lymphoblastic Leukemia

IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that International Biotechnology Center (IBC) Generium, a leading Russian biopharmaceutical company, focused on developing and commercialising pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate ...

Tuesday 3rd December 2019

IONTAS, Adaptate Enter Antibodies Alliance

To generate and optimize antibodies for novel immuno-oncology targets

IONTAS and Adaptate Biotherapeutics Collaborate to Identify Optimised Antibodies for Novel Cancer Targets

  IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ propriet...

IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets.

Cambridge, UK, 03 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimise antibodies for novel immuno-oncology targets, includin...

Wednesday 31st July 2019

Teva, Iontas enter deal for biotherapeutics development

Teva Pharmaceuticals and Iontas have partnered to optimize human antibodies to be used for biotherapeutics.  -More- 

Tuesday 30th July 2019

IONTAS, Teva announce new antibody optimisation agreement

Teva recently halted its Ajovy clinical development.

Monday 29th July 2019

IONTAS announces new antibody optimisation agreement with Teva Pharmaceuticals.

Cambridge, UK, 29 July 2019: IONTAS Limited (IONTAS), a leader in antibody discovery and optimisation of human monoclonal antibody libraries, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics. Under the terms of the agreement, IONTAS will initially apply its proprietary tech...

IONTAS Announces New Antibody Optimisation Agreement With Teva Pharmaceuticals

IONTAS Limited (IONTAS), a leader in antibody discovery and optimisation of human monoclonal antibody libraries, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics. Under the terms of the agreement, IONTAS will initially apply its proprietary technologies to provide Teva with a p...

IONTAS, Teva Enter Antibody Optimization Agreement

Partnership includes options for the screening of biophysical properties suitable for developable antibodies.


Quick Search

News Quicklinks